Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 53-59

  Sader, Helio S ^a   Castanheira, Mariana ^a   Flamm, Robert K ^a   Mendes, Rodrigo E ^a   Farrell, David J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae; CRE; ESBL; KPC; Pseudomonas aeruginosa

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAMASE; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL DNA;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CITROBACTER; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL PATIENT; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROARRAY ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; VENTILATOR ASSOCIATED PNEUMONIA; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DRUG EFFECTS; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CEFTAZIDIME; CROSS INFECTION; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROARRAY ANALYSIS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; UNITED STATES;

EID: 84934963355     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.02.022     Document Type: Article

References (30)

1. Hanberger H, Arman D, Gill H., Jindrak V, Kalenic S, Kurcz A., et al. Surveillance of microbial resistance in European intensive care units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2009; 35:91-100.
2. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N EnglJ Med 2010; 362:1804-13.
3. Boucher HW, Talbot GH, Benjamin Jr DK, Bradley J, Guidos RJ, Jones R.N., et al. 10×'20 progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685-94.
4. Forest Pharmaceuticals. AVYCAZ™ package insert. Cincinnati, OH: Forest Pharmaceuticals; 2015. {http://www.avycaz.com) [accessed 26 February 2015].
5. Coleman K. Diazabicyclooctanes: a potent new class of non-β-lactam β-lactamase inhibitors. CurrOpin Microbiol 2011; 14:550-5.
6. Sader HS, Castanheira M, Flamm R.K., Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 2014; 58:1684-92.
7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. In: Document M07-A9. Wayne, PA: CLSI; 2012.
8. Magiorakos AP, Srinivasan A, Carey R.B., Carmeli Y., Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. In: Document M100-S24. Wayne, PA: CLSI; 2014.
10. Castanheira M, Farrell SE, Krause K.M., Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014; 58:833-8.
11. Castanheira M, Farrell SE, Deshpande L.M., Mendes RE, Jones RN. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 USA hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 2013; 57:3012-20.
12. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, January; 2014. {http://www.eucast.org/clinical-breakpoints/) [accessed January 2014].
13. Epson EE, Pisney LM, Wendt J.M., MacCannell DR, Janelle SJ, Kitchel B, et al. Carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-β-lactamase at an acute care hospital, Colorado, 2012. Infect Control Hosp Epidemiol 2014; 35:390-7.
14. Kollef KE, Schramm GE, Wills A.R., Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant Gram-negative bacteria. Chest 2008; 134:281-7.
15. Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, et al.; SAEI/SAMPAC Bacteremia Group. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012; 56:472-8.
16. Morata L, Cobos-Trigueros N, Martínez JA, Soriano A., Almela M, Marco F, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56:4833-7.
17. Patel G, Huprikar S, Factor S.H., Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106.
18. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028-33.
19. Tumbarello M, Sanguinetti M, Montuori E., Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-94.
20. Zavascki AP, Barth AL, Gonçalves AL, Moro A.L., Fernandes JF, Martins AF, et al. The influence of metallo-β-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 2006; 58:387-92.
21. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
22. Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011; 27:163-205.
23. Sader HS, Farrell DJ, Flamm R.K., Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014; 78:443-8.
24. Tzouvelekis LS, Markogiannakis A, Psichogiou M., Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
25. Carmeli Y, Akova M, Cornaglia G., Daikos GL, Garau J, Harbarth S, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010; 16: 102-11.
26. Falagas ME, Lourida P, Poulikakos P., Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58:654-63.
27. Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E; Antibiotic Resistance Surveillance Group. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in The Netherlands. Eur J Clin Microbiol Infect Dis 2013; 32:283-8.
28. Joseph NM, Sistla S, Dutta T.K., Badhe AS, Parija SC. Ventilator-associated pneumonia: a review. EurJ Intern Med 2010; 21:360-8.
29. Sievert DM, Ricks P, Edwards J.R., Schneider A., Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14.
30. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-40.